Potential implications of mesenchymal stem cells in cancer therapy

Dai, Long‐Jun; Moniri, Mani Roshan; Zeng, Zhirong; Zhou, Jeff X.; Rayat, Jarrett; Warnock, Garth L.

doi:10.1016/j.canlet.2011.02.012

Cited by 89 publications

(69 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The direct effects of MSCs on tumor cell viability are mainly attributed to their intrinsic antitumor properties. 7 Our data suggest that cancer cell-induced chemotactic effects on MSCs have an important role in the cell-to-cell interactions. Related chemotactic factors are to be identified in forthcoming studies.…”

Section: Dynamic Observation Of Msc Migration Toward Pancreatic Cancementioning

confidence: 68%

“…7 Tumor-directed migration and incorporation of MSCs have been demonstrated in a number of preclinical studies in vitro using transwell migration assays, and in vivo using animal tumor models. The homing capacity of MSCs has been demonstrated with almost all tested human cancer cell lines, including lung cancer, 8 malignant gliomas, 9--11 Kaposi's sarcomas, 12 breast cancer, 13,14 colon carcinoma, 15 pancreatic cancer, 16,17 melanoma 18 and ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

Sun

Rayat

et al. 2012

Cancer Gene Ther

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have attracted great interest in cancer therapy owing to their tumor-oriented homing capacity and the feasibility of autologous transplantation. Currently, pancreatic cancer patients face a very poor prognosis, primarily due to the lack of therapeutic strategies with an effective degree of specificity. Anticancer gene-engineered MSCs specifically target tumor sites and can produce anticancer agents locally and constantly. This study was performed to characterize pancreasderived MSCs and investigate the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-engineered MSCs on pancreatic cancer cells under different culture conditions. Pancreas-derived MSCs exhibited positive expression on CD44, CD73, CD95, CD105, negative on CD34 and differentiated into adipogenic and osteogenic cells. TRAIL expression was assessed by both enzyme-linked immunosorbent assay and western blot analysis. Different patterns of TRAIL receptor expression were observed on the pancreatic cancer cell lines, including PANC1, HP62, ASPC1, TRM6 and BXPC3. Cell viability was assessed using a real-time monitoring system. Pancreatic cancer cell death was proportionally related to conditioned media from MSC nsTRAIL and MSC stTRAIL . The results suggest that MSCs exhibit intrinsic inhibition of pancreatic cancer cells and that this effect can be potentiated by TRAIL-transfection on death receptor-bearing cell types.

show abstract

Section: Dynamic Observation Of Msc Migration Toward Pancreatic Cancementioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

Sun

Rayat

et al. 2012

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…In recent years, MSCs have been extensively demonstrated possessing multilineage differentiation potential, anti-inflammatory function and immunomodulatory properties [5]. More recently, the tumor-trophic and migratory properties of MSCs demonstrated in various pre-clinical models has emerged an interesting concept of using MSCs as carrier for anti-cancer drug/gene delivery [6,7]. This notion also appears to be supported by several studies showing antitumor effects of MSCs [8][9][10].…”

Section: Introductionmentioning

confidence: 90%

Mesenchymal Stem/Stromal Cells Exert Trophic Effect on Colorectal Cancer Metastasis to the Liver

Hernanda¹,

Gonzalez²

2016

J Liver

View full text Add to dashboard Cite

Colorectal Cancer (CRC) is the third most common cancer in the world. CRC tends to metastasize to the liver, which may occur in 20% to 70% of patients and represents the major cause of death. Mesenchymal Stem/stromal cells (MSCs) have shown to be able to migrate to CRC site and play an important role in tumor progression. We have previously identified a resident MSC population in the liver. Therefore, this study aims to investigate whether there is infiltration of MSCs into patient CRC Liver Metastasis (CRC-LM) and their potential effects on tumor cell growth. By culturing resected patient CRC-LM tissue, we observed the emerging of fibroblast-like cells. Further phenotype and functional characterization confirmed their bonafide MSCs features. In situ staining with a well-established MSCs marker showed a significant enrichment of candidate MSCs in patient CRC-LM, particularly the tumor-stromal area. Moreover, MSCs secreted trophic factors significantly increased colony formation and growth of a metastatic CRC cell line. In summary, we found infiltration and enrichment of MSCs in CRC-LM patient, which could in turn nourish tumor cells.

show abstract

“…From a large number of members in the stem cells class, MSCs are the first type to be employed in clinical practice, particularly in regenerative medicine and tissue engineering field, mainly in view of the fact that they possess the ability for large-scale proliferation, self-regeneration, multipotent differentiation and suitability for autologous transplantation. In this view, therapeutically advantageous features of MSCs are existing possibilities for easy isolation and acquisition, fast expansion in culture, feasibility of autologous transplantation and their significant paracrine effects [5,6,[8][9][10]. In the course of the proliferation and differentiation processes, MSCs cooperate with other cells both through cell-cell interactions and paracrine signalizations (growth factors, cytokines, antifibrotic or angiogenic mediators) [11].…”

Section: Introductionmentioning

confidence: 99%

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Ackova¹,

Kanjevac²,

Rimondini³

et al. 2016

PRA

View full text Add to dashboard Cite

Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses' directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.

show abstract

Potential implications of mesenchymal stem cells in cancer therapy

Cited by 89 publications

References 118 publications

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

Mesenchymal Stem/Stromal Cells Exert Trophic Effect on Colorectal Cancer Metastasis to the Liver

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Contact Info

Product

Resources

About